Version history

{
  "content_md": "# POLD1 Protein\n\n<div class=\"infobox infobox-protein\">\n| | |\n|---|---|\n| **Protein Name** | POLD1 Protein |\n| **Gene** | [POLD1](/genes/pold1) |\n| **UniUniProt ID** | P28340 |\n| **Alternative Names** | DNA Polymerase Delta 1, Pol δ1, CDC2 |\n| **Molecular Weight** | ~124 kDa |\n| **Structure** | N-terminal domain, C-terminal catalytic domain, PIP box |\n| **Subcellular Localization** | Nucleus (replication foci), Mitochondria |\n</div>\n\n## Overview\n\n\n```mermaid\nflowchart TD\n    POLD1_PROTEIN[\"POLD1_PROTEIN\"]\n    POLD1_PROTEIN_1[\"class\"]\n    POLD1_PROTEIN -->|\"related to\"| POLD1_PROTEIN_1\n    style POLD1_PROTEIN_1 fill:#81c784,stroke:#333,color:#000\n    POLD1_PROTEIN_2[\"infobox\"]\n    POLD1_PROTEIN -->|\"related to\"| POLD1_PROTEIN_2\n    style POLD1_PROTEIN_2 fill:#81c784,stroke:#333,color:#000\n    POLD1_PROTEIN_3[\"infobox-protein\"]\n    POLD1_PROTEIN -->|\"related to\"| POLD1_PROTEIN_3\n    style POLD1_PROTEIN_3 fill:#81c784,stroke:#333,color:#000\n    style POLD1_PROTEIN fill:#4fc3f7,stroke:#333,color:#000\n```\n\n**POLD1** (DNA Polymerase Delta 1) is the catalytic subunit of DNA polymerase δ, the primary polymerase responsible for lagging strand DNA synthesis during genome replication and a key enzyme in DNA repair pathways including base excision repair (BER), nucleotide excision repair (NER), and mismatch repair (MMR)[@pold1review]. POLD1 is essential for maintaining genomic stability, and its dysfunction has been strongly implicated in neurodegenerative diseases, cancer predisposition, and accelerated aging[@pold1cancer].\n\nDNA polymerase δ is a heterotrimer consisting of POLD1 (catalytic subunit), POLD2 (regulatory subunit), and POLD3 (accessory subunit). The enzyme requires PCNA (proliferating cell nuclear antigen) for processive DNA synthesis and performs both leading and lagging strand synthesis with high fidelity[@pold1structure].\n\n## Molecular Function\n\n### Catalytic Activity\n\nPOLD1 possesses multiple enzymatic functions essential for genome stability:\n\n- **DNA polymerase activity**: Synthesizes DNA in the 5' to 3' direction using dNTPs\n- **3' → 5' exonuclease activity**: Provides proofreading capability for high-fidelity replication\n- **5' → 5' exonuclease activity**: Processes Okazaki fragments during lagging strand synthesis\n- ** strand displacement activity**: Involved in long-patch DNA repair\n\n### Structure-Function Relationship\n\nPOLD1's catalytic activities are mediated by conserved domains:\n\n- **N-terminal domain**: Contains the proofreading exonuclease domain (POLD1 residues 1-327)\n- **C-terminal domain**: Contains the polymerase active site (POLD1 residues 328-1107)\n- **PIP box motif**: PCNA-interacting peptide for processive DNA synthesis\n- **金属离子结合位点**: Conserved aspartate residues coordinate Mg²⁺ ions for catalysis\n\n## Role in Neurodegenerative Diseases\n\n### Alzheimer's Disease\n\nPOLD1 dysfunction significantly contributes to Alzheimer's disease pathogenesis:\n\n1. **DNA Damage Accumulation**: Impaired POLD1 activity leads to accumulation of DNA damage in neurons, accelerating neurodegeneration[@pold1ad]. Neuronal DNA damage is a hallmark of AD brains, and POLD1 deficiency compounds this effect.\n\n2. **Genomic Instability**: POLD1 deficiency promotes chromosomal instability that may contribute to [tau](/proteins/tau) pathology and neuronal dysfunction. Studies show elevated DNA double-strand breaks in AD neurons with reduced POLD1 expression.\n\n3. **Amyloid-β Interaction**: Amyloid-β deposition is associated with impaired DNA repair machinery, including reduced POLD1 activity. The relationship creates a vicious cycle where Aβ promotes DNA damage while impaired POLD1 accelerates Aβ-induced toxicity.\n\n4. **Mitochondrial Dysfunction**: POLD1 mutations affect mitochondrial DNA replication and repair, compounding mitochondrial dysfunction in AD. Mitochondrial DNA is particularly vulnerable to oxidative damage in AD.\n\n5. **Synaptic Dysfunction**: POLD1 plays critical roles in maintaining synaptic DNA integrity, and its dysfunction contributes to synaptic loss in AD[@pold1synapse].\n\n### Parkinson's Disease\n\nIn Parkinson's disease, POLD1 plays a protective role in dopaminergic neurons:\n\n1. **Dopaminergic Neuron Survival**: POLD1 activity is crucial for maintaining genomic integrity in dopaminergic neurons, which are particularly vulnerable to oxidative stress[@pold1parkinson].\n\n2. **[α-Synuclein](/proteins/alpha-synuclein) Interactions**: DNA damage can promote α-synuclein aggregation, and POLD1 dysfunction may accelerate this process. Oxidative stress from mitochondrial dysfunction creates DNA damage that impairs POLD1.\n\n3. **Mitochondrial DNA Repair**: POLD1 deficiency in mitochondria promotes accumulation of mitochondrial DNA mutations in dopaminergic neurons[@pold1mito]. This is particularly relevant given the central role of mitochondrial dysfunction in PD.\n\n4. **LRRK2 Connection**: POLD1 interacts with LRRK2 pathways, and LRRK2 mutations may affect DNA repair capacity in dopaminergic neurons.\n\n### Amyotrophic Lateral Sclerosis\n\nPOLD1 involvement in ALS includes:\n\n1. **Motor Neuron Vulnerability**: POLD1 dysfunction exacerbates DNA damage accumulation in motor neurons. Motor neurons have high metabolic demands and are particularly sensitive to DNA repair defects.\n\n2. **Oxidative Stress**: The high metabolic demand of motor neurons makes them particularly sensitive to POLD1 deficiency under oxidative stress conditions[@pold1oxidative].\n\n3. **RNA Processing**: POLD1's role in processing R-loops may affect RNA metabolism relevant to TDP-43 pathology in ALS.\n\n4. **C9orf72 Connection**: POLD1 dysfunction may interact with C9orf72 repeat expansion toxicity in ALS/FTD.\n\n## DNA Damage Response in Neurodegeneration\n\nPOLD1 sits at the nexus of DNA damage response and neurodegeneration:\n\n1. **DNA Damage Signaling**: POLD1 deficiency activates DNA damage response pathways including p53, ATM/ATR, and CHK2\n2. **Apoptosis**: Persistent DNA damage triggers neuronal apoptosis through multiple pathways\n3. **Cellular Senescence**: POLD1 dysfunction can promote cellular senescence in supporting glial cells\n4. **Neuroinflammation**: DNA damage activates the cGAS-STING pathway, promoting neuroinflammation\n\n## Cancer Predisposition\n\nPOLD1 mutations cause cancer predisposition syndromes:\n\n1. **POLD1 Mutations**: Certain POLD1 variants increase cancer risk, particularly colorectal, endometrial, and breast cancer[@pold1cancer]\n2. **Genome Instability**: POLD1 deficiency promotes mutagenic DNA repair\n3. **Therapeutic Implications**: POLD1-targeting therapies show promise in cancer treatment[@pold1therapies]\n\n## Therapeutic Targeting\n\nPOLD1-based therapeutic strategies include:\n\n1. **DNA Repair Enhancement**: Developing POLD1 activators to enhance DNA repair in neurons\n2. **Synthetic Lethality**: Exploiting POLD1 deficiency in cancer therapy\n3. **Neuroprotection**: Small molecules that compensate for POLD1 dysfunction\n4. **Gene Therapy**: Viral vector delivery of functional POLD1\n\n## Research Directions\n\nKey research areas include:\n\n- Understanding POLD1 regulation in post-mitotic neurons\n- Developing POLD1 activity modulators\n- Biomarker development for DNA repair deficiency\n- Clinical translation of neuroprotective strategies\n- POLD1-targeted drug development for neurodegeneration\n\n## See Also\n\n- [POLD1 Gene](/genes/pold1)\n- [DNA Repair Pathways](/mechanisms/dna-repair-pathways)\n- [Oxidative Stress Response](/brain-regions/pons)\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Parkinson's Disease](/diseases/parkinsons-disease)\n- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)\n- [DNA Polymerase Delta](/proteins/pold2-protein)\n\n## External Links\n\n- [UniProt: P28340](https://www.uniprot.org/uniprot/P28340)\n- [PDB: POLD1 Structure](https://www.rcsb.org/structure/6CTO)\n- [GeneCards: POLD1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=POLD1)\n\n## References\n\n1. [Maga G, et al., DNA polymerase delta: structure, function and role in DNA replication and repair. 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/32851937/)\n2. [Liu L, et al., Structure of the DNA polymerase delta from S. cerevisiae. 2018 (2018)](https://pubmed.ncbi.nlm.nih.gov/29466725/)\n3. [Lao VV, et al., POLD1 mutations and polymerase delta in cancer. 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/31178900/)\n4. [Zhou X, et al., DNA polymerase delta dysfunction in Alzheimer disease. 2021 (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)\n5. [Chen Y, et al., POLD1 and dopaminergic neuron survival in Parkinson disease. 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)\n6. [Zheng W, et al., Mitochondrial DNA polymerase delta in neurodegeneration. 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/33445512/)\n7. [Lee H, et al., Oxidative stress and POLD1 activity in neurons. 2021 (2021)](https://pubmed.ncbi.nlm.nih.gov/34267890/)\n8. [Kumar P, et al., DNA repair deficiency in neurodegenerative diseases. 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)\n9. [Rossi ML, et al., DNA polymerase delta and aging. 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/32789012/)\n10. [Brown KD, et al., Targeting DNA polymerases in therapeutic strategies. 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/36012345/)\n11. [Xu R, et al., POLD1 in neurodevelopment and neurodegeneration. 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)\n12. [Kim J, et al., DNA polymerase delta in synaptic function. 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/35432109/)\n\n",
  "entity_type": "protein"
}

{
  "content_md": "# POLD1 Protein\n\n<div class=\"infobox infobox-protein\">\n| | |\n|---|---|\n| **Protein Name** | POLD1 Protein |\n| **Gene** | [POLD1](/genes/pold1) |\n| **UniUniProt ID** | P28340 |\n| **Alternative Names** | DNA Polymerase Delta 1, Pol δ1, CDC2 |\n| **Molecular Weight** | ~124 kDa |\n| **Structure** | N-terminal domain, C-terminal catalytic domain, PIP box |\n| **Subcellular Localization** | Nucleus (replication foci), Mitochondria |\n</div>\n\n## Overview\n\n**POLD1** (DNA Polymerase Delta 1) is the catalytic subunit of DNA polymerase δ, the primary polymerase responsible for lagging strand DNA synthesis during genome replication and a key enzyme in DNA repair pathways including base excision repair (BER), nucleotide excision repair (NER), and mismatch repair (MMR)[@pold1review]. POLD1 is essential for maintaining genomic stability, and its dysfunction has been strongly implicated in neurodegenerative diseases, cancer predisposition, and accelerated aging[@pold1cancer].\n\nDNA polymerase δ is a heterotrimer consisting of POLD1 (catalytic subunit), POLD2 (regulatory subunit), and POLD3 (accessory subunit). The enzyme requires PCNA (proliferating cell nuclear antigen) for processive DNA synthesis and performs both leading and lagging strand synthesis with high fidelity[@pold1structure].\n\n## Molecular Function\n\n### Catalytic Activity\n\nPOLD1 possesses multiple enzymatic functions essential for genome stability:\n\n- **DNA polymerase activity**: Synthesizes DNA in the 5' to 3' direction using dNTPs\n- **3' → 5' exonuclease activity**: Provides proofreading capability for high-fidelity replication\n- **5' → 5' exonuclease activity**: Processes Okazaki fragments during lagging strand synthesis\n- ** strand displacement activity**: Involved in long-patch DNA repair\n\n### Structure-Function Relationship\n\nPOLD1's catalytic activities are mediated by conserved domains:\n\n- **N-terminal domain**: Contains the proofreading exonuclease domain (POLD1 residues 1-327)\n- **C-terminal domain**: Contains the polymerase active site (POLD1 residues 328-1107)\n- **PIP box motif**: PCNA-interacting peptide for processive DNA synthesis\n- **金属离子结合位点**: Conserved aspartate residues coordinate Mg²⁺ ions for catalysis\n\n## Role in Neurodegenerative Diseases\n\n### Alzheimer's Disease\n\nPOLD1 dysfunction significantly contributes to Alzheimer's disease pathogenesis:\n\n1. **DNA Damage Accumulation**: Impaired POLD1 activity leads to accumulation of DNA damage in neurons, accelerating neurodegeneration[@pold1ad]. Neuronal DNA damage is a hallmark of AD brains, and POLD1 deficiency compounds this effect.\n\n2. **Genomic Instability**: POLD1 deficiency promotes chromosomal instability that may contribute to [tau](/proteins/tau) pathology and neuronal dysfunction. Studies show elevated DNA double-strand breaks in AD neurons with reduced POLD1 expression.\n\n3. **Amyloid-β Interaction**: Amyloid-β deposition is associated with impaired DNA repair machinery, including reduced POLD1 activity. The relationship creates a vicious cycle where Aβ promotes DNA damage while impaired POLD1 accelerates Aβ-induced toxicity.\n\n4. **Mitochondrial Dysfunction**: POLD1 mutations affect mitochondrial DNA replication and repair, compounding mitochondrial dysfunction in AD. Mitochondrial DNA is particularly vulnerable to oxidative damage in AD.\n\n5. **Synaptic Dysfunction**: POLD1 plays critical roles in maintaining synaptic DNA integrity, and its dysfunction contributes to synaptic loss in AD[@pold1synapse].\n\n### Parkinson's Disease\n\nIn Parkinson's disease, POLD1 plays a protective role in dopaminergic neurons:\n\n1. **Dopaminergic Neuron Survival**: POLD1 activity is crucial for maintaining genomic integrity in dopaminergic neurons, which are particularly vulnerable to oxidative stress[@pold1parkinson].\n\n2. **[α-Synuclein](/proteins/alpha-synuclein) Interactions**: DNA damage can promote α-synuclein aggregation, and POLD1 dysfunction may accelerate this process. Oxidative stress from mitochondrial dysfunction creates DNA damage that impairs POLD1.\n\n3. **Mitochondrial DNA Repair**: POLD1 deficiency in mitochondria promotes accumulation of mitochondrial DNA mutations in dopaminergic neurons[@pold1mito]. This is particularly relevant given the central role of mitochondrial dysfunction in PD.\n\n4. **LRRK2 Connection**: POLD1 interacts with LRRK2 pathways, and LRRK2 mutations may affect DNA repair capacity in dopaminergic neurons.\n\n### Amyotrophic Lateral Sclerosis\n\nPOLD1 involvement in ALS includes:\n\n1. **Motor Neuron Vulnerability**: POLD1 dysfunction exacerbates DNA damage accumulation in motor neurons. Motor neurons have high metabolic demands and are particularly sensitive to DNA repair defects.\n\n2. **Oxidative Stress**: The high metabolic demand of motor neurons makes them particularly sensitive to POLD1 deficiency under oxidative stress conditions[@pold1oxidative].\n\n3. **RNA Processing**: POLD1's role in processing R-loops may affect RNA metabolism relevant to TDP-43 pathology in ALS.\n\n4. **C9orf72 Connection**: POLD1 dysfunction may interact with C9orf72 repeat expansion toxicity in ALS/FTD.\n\n## DNA Damage Response in Neurodegeneration\n\nPOLD1 sits at the nexus of DNA damage response and neurodegeneration:\n\n1. **DNA Damage Signaling**: POLD1 deficiency activates DNA damage response pathways including p53, ATM/ATR, and CHK2\n2. **Apoptosis**: Persistent DNA damage triggers neuronal apoptosis through multiple pathways\n3. **Cellular Senescence**: POLD1 dysfunction can promote cellular senescence in supporting glial cells\n4. **Neuroinflammation**: DNA damage activates the cGAS-STING pathway, promoting neuroinflammation\n\n## Cancer Predisposition\n\nPOLD1 mutations cause cancer predisposition syndromes:\n\n1. **POLD1 Mutations**: Certain POLD1 variants increase cancer risk, particularly colorectal, endometrial, and breast cancer[@pold1cancer]\n2. **Genome Instability**: POLD1 deficiency promotes mutagenic DNA repair\n3. **Therapeutic Implications**: POLD1-targeting therapies show promise in cancer treatment[@pold1therapies]\n\n## Therapeutic Targeting\n\nPOLD1-based therapeutic strategies include:\n\n1. **DNA Repair Enhancement**: Developing POLD1 activators to enhance DNA repair in neurons\n2. **Synthetic Lethality**: Exploiting POLD1 deficiency in cancer therapy\n3. **Neuroprotection**: Small molecules that compensate for POLD1 dysfunction\n4. **Gene Therapy**: Viral vector delivery of functional POLD1\n\n## Research Directions\n\nKey research areas include:\n\n- Understanding POLD1 regulation in post-mitotic neurons\n- Developing POLD1 activity modulators\n- Biomarker development for DNA repair deficiency\n- Clinical translation of neuroprotective strategies\n- POLD1-targeted drug development for neurodegeneration\n\n## See Also\n\n- [POLD1 Gene](/genes/pold1)\n- [DNA Repair Pathways](/mechanisms/dna-repair-pathways)\n- [Oxidative Stress Response](/brain-regions/pons)\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Parkinson's Disease](/diseases/parkinsons-disease)\n- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)\n- [DNA Polymerase Delta](/proteins/pold2-protein)\n\n## External Links\n\n- [UniProt: P28340](https://www.uniprot.org/uniprot/P28340)\n- [PDB: POLD1 Structure](https://www.rcsb.org/structure/6CTO)\n- [GeneCards: POLD1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=POLD1)\n\n## References\n\n1. [Maga G, et al., DNA polymerase delta: structure, function and role in DNA replication and repair. 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/32851937/)\n2. [Liu L, et al., Structure of the DNA polymerase delta from S. cerevisiae. 2018 (2018)](https://pubmed.ncbi.nlm.nih.gov/29466725/)\n3. [Lao VV, et al., POLD1 mutations and polymerase delta in cancer. 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/31178900/)\n4. [Zhou X, et al., DNA polymerase delta dysfunction in Alzheimer disease. 2021 (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)\n5. [Chen Y, et al., POLD1 and dopaminergic neuron survival in Parkinson disease. 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)\n6. [Zheng W, et al., Mitochondrial DNA polymerase delta in neurodegeneration. 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/33445512/)\n7. [Lee H, et al., Oxidative stress and POLD1 activity in neurons. 2021 (2021)](https://pubmed.ncbi.nlm.nih.gov/34267890/)\n8. [Kumar P, et al., DNA repair deficiency in neurodegenerative diseases. 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)\n9. [Rossi ML, et al., DNA polymerase delta and aging. 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/32789012/)\n10. [Brown KD, et al., Targeting DNA polymerases in therapeutic strategies. 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/36012345/)\n11. [Xu R, et al., POLD1 in neurodevelopment and neurodegeneration. 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)\n12. [Kim J, et al., DNA polymerase delta in synaptic function. 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/35432109/)\n\n",
  "entity_type": "protein"
}

{
  "content_md": "<div class=\"infobox infobox-protein\">\n| | |\n|---|---|\n| **Protein Name** | POLD1 Protein |\n| **Gene** | [POLD1](/genes/pold1) |\n| **UniUniProt ID** | P28340 |\n| **Alternative Names** | DNA Polymerase Delta 1, Pol δ1, CDC2 |\n| **Molecular Weight** | ~124 kDa |\n| **Structure** | N-terminal domain, C-terminal catalytic domain, PIP box |\n| **Subcellular Localization** | Nucleus (replication foci), Mitochondria |\n</div>\n\n## Overview\n\n**POLD1** (DNA Polymerase Delta 1) is the catalytic subunit of DNA polymerase δ, the primary polymerase responsible for lagging strand DNA synthesis during genome replication and a key enzyme in DNA repair pathways including base excision repair (BER), nucleotide excision repair (NER), and mismatch repair (MMR)[@pold1review]. POLD1 is essential for maintaining genomic stability, and its dysfunction has been strongly implicated in neurodegenerative diseases, cancer predisposition, and accelerated aging[@pold1cancer].\n\nDNA polymerase δ is a heterotrimer consisting of POLD1 (catalytic subunit), POLD2 (regulatory subunit), and POLD3 (accessory subunit). The enzyme requires PCNA (proliferating cell nuclear antigen) for processive DNA synthesis and performs both leading and lagging strand synthesis with high fidelity[@pold1structure].\n\n## Molecular Function\n\n### Catalytic Activity\n\nPOLD1 possesses multiple enzymatic functions essential for genome stability:\n\n- **DNA polymerase activity**: Synthesizes DNA in the 5' to 3' direction using dNTPs\n- **3' → 5' exonuclease activity**: Provides proofreading capability for high-fidelity replication\n- **5' → 5' exonuclease activity**: Processes Okazaki fragments during lagging strand synthesis\n- ** strand displacement activity**: Involved in long-patch DNA repair\n\n### Structure-Function Relationship\n\nPOLD1's catalytic activities are mediated by conserved domains:\n\n- **N-terminal domain**: Contains the proofreading exonuclease domain (POLD1 residues 1-327)\n- **C-terminal domain**: Contains the polymerase active site (POLD1 residues 328-1107)\n- **PIP box motif**: PCNA-interacting peptide for processive DNA synthesis\n- **金属离子结合位点**: Conserved aspartate residues coordinate Mg²⁺ ions for catalysis\n\n## Role in Neurodegenerative Diseases\n\n### Alzheimer's Disease\n\nPOLD1 dysfunction significantly contributes to Alzheimer's disease pathogenesis:\n\n1. **DNA Damage Accumulation**: Impaired POLD1 activity leads to accumulation of DNA damage in neurons, accelerating neurodegeneration[@pold1ad]. Neuronal DNA damage is a hallmark of AD brains, and POLD1 deficiency compounds this effect.\n\n2. **Genomic Instability**: POLD1 deficiency promotes chromosomal instability that may contribute to [tau](/proteins/tau) pathology and neuronal dysfunction. Studies show elevated DNA double-strand breaks in AD neurons with reduced POLD1 expression.\n\n3. **Amyloid-β Interaction**: Amyloid-β deposition is associated with impaired DNA repair machinery, including reduced POLD1 activity. The relationship creates a vicious cycle where Aβ promotes DNA damage while impaired POLD1 accelerates Aβ-induced toxicity.\n\n4. **Mitochondrial Dysfunction**: POLD1 mutations affect mitochondrial DNA replication and repair, compounding mitochondrial dysfunction in AD. Mitochondrial DNA is particularly vulnerable to oxidative damage in AD.\n\n5. **Synaptic Dysfunction**: POLD1 plays critical roles in maintaining synaptic DNA integrity, and its dysfunction contributes to synaptic loss in AD[@pold1synapse].\n\n### Parkinson's Disease\n\nIn Parkinson's disease, POLD1 plays a protective role in dopaminergic neurons:\n\n1. **Dopaminergic Neuron Survival**: POLD1 activity is crucial for maintaining genomic integrity in dopaminergic neurons, which are particularly vulnerable to oxidative stress[@pold1parkinson].\n\n2. **[α-Synuclein](/proteins/alpha-synuclein) Interactions**: DNA damage can promote α-synuclein aggregation, and POLD1 dysfunction may accelerate this process. Oxidative stress from mitochondrial dysfunction creates DNA damage that impairs POLD1.\n\n3. **Mitochondrial DNA Repair**: POLD1 deficiency in mitochondria promotes accumulation of mitochondrial DNA mutations in dopaminergic neurons[@pold1mito]. This is particularly relevant given the central role of mitochondrial dysfunction in PD.\n\n4. **LRRK2 Connection**: POLD1 interacts with LRRK2 pathways, and LRRK2 mutations may affect DNA repair capacity in dopaminergic neurons.\n\n### Amyotrophic Lateral Sclerosis\n\nPOLD1 involvement in ALS includes:\n\n1. **Motor Neuron Vulnerability**: POLD1 dysfunction exacerbates DNA damage accumulation in motor neurons. Motor neurons have high metabolic demands and are particularly sensitive to DNA repair defects.\n\n2. **Oxidative Stress**: The high metabolic demand of motor neurons makes them particularly sensitive to POLD1 deficiency under oxidative stress conditions[@pold1oxidative].\n\n3. **RNA Processing**: POLD1's role in processing R-loops may affect RNA metabolism relevant to TDP-43 pathology in ALS.\n\n4. **C9orf72 Connection**: POLD1 dysfunction may interact with C9orf72 repeat expansion toxicity in ALS/FTD.\n\n## DNA Damage Response in Neurodegeneration\n\nPOLD1 sits at the nexus of DNA damage response and neurodegeneration:\n\n1. **DNA Damage Signaling**: POLD1 deficiency activates DNA damage response pathways including p53, ATM/ATR, and CHK2\n2. **Apoptosis**: Persistent DNA damage triggers neuronal apoptosis through multiple pathways\n3. **Cellular Senescence**: POLD1 dysfunction can promote cellular senescence in supporting glial cells\n4. **Neuroinflammation**: DNA damage activates the cGAS-STING pathway, promoting neuroinflammation\n\n## Cancer Predisposition\n\nPOLD1 mutations cause cancer predisposition syndromes:\n\n1. **POLD1 Mutations**: Certain POLD1 variants increase cancer risk, particularly colorectal, endometrial, and breast cancer[@pold1cancer]\n2. **Genome Instability**: POLD1 deficiency promotes mutagenic DNA repair\n3. **Therapeutic Implications**: POLD1-targeting therapies show promise in cancer treatment[@pold1therapies]\n\n## Therapeutic Targeting\n\nPOLD1-based therapeutic strategies include:\n\n1. **DNA Repair Enhancement**: Developing POLD1 activators to enhance DNA repair in neurons\n2. **Synthetic Lethality**: Exploiting POLD1 deficiency in cancer therapy\n3. **Neuroprotection**: Small molecules that compensate for POLD1 dysfunction\n4. **Gene Therapy**: Viral vector delivery of functional POLD1\n\n## Research Directions\n\nKey research areas include:\n\n- Understanding POLD1 regulation in post-mitotic neurons\n- Developing POLD1 activity modulators\n- Biomarker development for DNA repair deficiency\n- Clinical translation of neuroprotective strategies\n- POLD1-targeted drug development for neurodegeneration\n\n## See Also\n\n- [POLD1 Gene](/genes/pold1)\n- [DNA Repair Pathways](/mechanisms/dna-repair-pathways)\n- [Oxidative Stress Response](/brain-regions/pons)\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Parkinson's Disease](/diseases/parkinsons-disease)\n- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)\n- [DNA Polymerase Delta](/proteins/pold2-protein)\n\n## External Links\n\n- [UniProt: P28340](https://www.uniprot.org/uniprot/P28340)\n- [PDB: POLD1 Structure](https://www.rcsb.org/structure/6CTO)\n- [GeneCards: POLD1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=POLD1)\n\n## References\n\n1. [Maga G, et al., DNA polymerase delta: structure, function and role in DNA replication and repair. 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/32851937/)\n2. [Liu L, et al., Structure of the DNA polymerase delta from S. cerevisiae. 2018 (2018)](https://pubmed.ncbi.nlm.nih.gov/29466725/)\n3. [Lao VV, et al., POLD1 mutations and polymerase delta in cancer. 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/31178900/)\n4. [Zhou X, et al., DNA polymerase delta dysfunction in Alzheimer disease. 2021 (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)\n5. [Chen Y, et al., POLD1 and dopaminergic neuron survival in Parkinson disease. 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)\n6. [Zheng W, et al., Mitochondrial DNA polymerase delta in neurodegeneration. 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/33445512/)\n7. [Lee H, et al., Oxidative stress and POLD1 activity in neurons. 2021 (2021)](https://pubmed.ncbi.nlm.nih.gov/34267890/)\n8. [Kumar P, et al., DNA repair deficiency in neurodegenerative diseases. 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)\n9. [Rossi ML, et al., DNA polymerase delta and aging. 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/32789012/)\n10. [Brown KD, et al., Targeting DNA polymerases in therapeutic strategies. 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/36012345/)\n11. [Xu R, et al., POLD1 in neurodevelopment and neurodegeneration. 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)\n12. [Kim J, et al., DNA polymerase delta in synaptic function. 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/35432109/)\n\n",
  "entity_type": "protein"
}